Quinoprotein adducts accumulate in the substantia nigra of aged rats and correlate with dopamine-induced toxicity in SH-SY5Y cells

Neurochemical Research

Volumn 36, Issue 11, 2011, Pages 2169-2175

  Wang, Na ^a   Wang, Yan ^a   Yu, Guohua ^a   Yuan, Chonggang ^a   Ma, Jiyan ^a,b  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Aging; Dopamine; Dopamine quinone; Lipid peroxidation; Parkinson disease; Quinoprotein adduct

Indexed keywords

DOPAMINE; QUINOPROTEIN; SULFORAPHANE; UNCLASSIFIED DRUG;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CAUDATE NUCLEUS; CELL VIABILITY; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; HIPPOCAMPUS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIPID PEROXIDATION; MALE; NONHUMAN; PARKINSON DISEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; SUBSTANTIA NIGRA PARS COMPACTA; SUPERNATANT;

AGING; ANIMALS; CYSTEINE; DOPAMINE; DOPAMINE ANTAGONISTS; DOPAMINERGIC NEURONS; HUMANS; HYDROQUINONES; LIPID PEROXIDATION; MALE; NERVE TISSUE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; THIOCYANATES; TUMOR CELLS, CULTURED;

RATTUS;

EID: 80055014261     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-011-0541-z     Document Type: Article

References (38)

1. LM de Lau MM Breteler 2006 Epidemiology of Parkinson's disease Lancet Neurol 5 525 535 16713924 10.1016/S1474-4422(06)70471-9 (Pubitemid 44262284)
2. RL Nussbaum CE Ellis 2003 Alzheimer's disease and Parkinson's disease N Engl J Med 348 1356 1364 12672864 10.1056/NEJM2003ra020003 1:CAS:528: DC%2BD3sXis1egt7c%3D (Pubitemid 36384104)
3. TG Hastings DA Lewis MJ Zigmond 1996 Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections Proc Natl Acad Sci USA 93 1956 1961 8700866 10.1073/pnas.93.5.1956 1:CAS:528:DyaK28XhsFartLw%3D (Pubitemid 26079862)
4. RE Colebrooke, et al. 2006 Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease Eur J Neurosci 24 2622 2630 17100850 10.1111/j.1460-9568.2006.05143.x (Pubitemid 44726774)
5. WM Caudle, et al. 2007 Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration J Neurosci 27 8138 8148 17652604 10.1523/JNEUROSCI.0319-07.2007 1:CAS:528:DC%2BD2sXoslSjtrk%3D (Pubitemid 47173329)
6. L Chen, et al. 2008 Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice J Neurosci 28 425 433 18184785 10.1523/JNEUROSCI.3602-07.2008
7. EV Mosharov, et al. 2009 Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons Neuron 62 218 229 19409267 10.1016/j.neuron.2009.01.033 1:CAS:528:DC%2BD1MXlvFSrtrs%3D
8. G Eisenhofer IJ Kopin DS Goldstein 2004 Catecholamine metabolism: a contemporary view with implications for physiology and medicine Pharmacol Rev 56 331 349 15317907 10.1124/pr.56.3.1 1:CAS:528:DC%2BD2cXotVKjtbs%3D (Pubitemid 39096594)
9. WM Caudle, et al. 2008 Altered vesicular dopamine storage in Parkinson's disease: a premature demise Trends Neurosci 31 303 308 18471904 10.1016/j.tins.2008.02.010 1:CAS:528:DC%2BD1cXmvV2isb0%3D
10. DG Graham 1978 Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones Mol Pharmacol 14 633 643 98706 1:CAS:528:DyaE1cXlsF2is7w%3D (Pubitemid 8402469)
11. D Sulzer L Zecca 2000 Intraneuronal dopamine-quinone synthesis: a review Neurotox Res 1 181 195 12835101 10.1007/BF03033289 1:CAS:528: DC%2BD3cXjsFCls7w%3D
12. JL Bolton, et al. 2000 Role of quinones in toxicology Chem Res Toxicol 13 135 160 10725110 10.1021/tx9902082 1:CAS:528:DC%2BD3cXht1aitr4%3D (Pubitemid 30169958)
13. SB Berman MJ Zigmond TG Hastings 1996 Modification of dopamine transporter function: effect of reactive oxygen species and dopamine J Neurochem 67 593 600 8764584 10.1046/j.1471-4159.1996.67020593.x 1:CAS:528: DyaK28XksFCjtr4%3D (Pubitemid 26255653)
14. SB Berman TG Hastings 1999 Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease J Neurochem 73 1127 1137 10461904 10.1046/j.1471-4159.1999.0731127.x 1:CAS:528:DyaK1MXlsVOitL4%3D (Pubitemid 29395471)
15. MJ LaVoie, et al. 2005 Dopamine covalently modifies and functionally inactivates parkin Nat Med 11 1214 1221 16227987 10.1038/nm1314 1:CAS:528:DC%2BD2MXhtFOhsLvP (Pubitemid 43093669)
16. RE Zigmond MA Schwarzschild AR Rittenhouse 1989 Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation Annu Rev Neurosci 12 415 461 2564757 10.1146/annurev.ne.12. 030189.002215 1:CAS:528:DyaL1MXhvVKjtr8%3D (Pubitemid 19085457)
17. JW Haycock DA Haycock 1991 Tyrosine hydroxylase in rat brain dopaminergic nerve terminals. Multiple-site phosphorylation in vivo and in synaptosomes J Biol Chem 266 5650 5657 1672315 1:CAS:528:DyaK3MXitVCmuro%3D
18. D Zhang, et al. 2007 Protein kinase C delta negatively regulates tyrosine hydroxylase activity and dopamine synthesis by enhancing protein phosphatase-2A activity in dopaminergic neurons J Neurosci 27 5349 5362 17507557 10.1523/JNEUROSCI.4107-06.2007 1:CAS:528:DC%2BD2sXlvFGhsrw%3D (Pubitemid 46790158)
19. MA Paz, et al. 1991 Specific detection of quinoproteins by redox-cycling staining J Biol Chem 266 689 692 1702437 1:CAS:528:DyaK3MXpslWhsw%3D%3D (Pubitemid 21907168)
20. A Tarozzi, et al. 2009 Sulforaphane as an inducer of glutathione prevents oxidative stress-induced cell death in a dopaminergic-like neuroblastoma cell line J Neurochem 111 1161 1171 19780897 10.1111/j.1471-4159.2009.06394.x 1:CAS:528:DC%2BD1MXhsVyrsbfP
21. AM Snyder JR Connor 2009 Iron, the substantia nigra and related neurological disorders Biochim Biophys Acta 1790 606 614 18778755 1:CAS:528:DC%2BD1MXnt1yjtLg%3D
22. L Giovannelli, et al. 2003 Vulnerability to DNA damage in the aging rat substantia nigra: a study with the comet assay Brain Res 969 244 247 12676385 10.1016/S0006-8993(03)02275-3 1:CAS:528:DC%2BD3sXisV2msbY%3D (Pubitemid 36369632)
23. N Hattoria, et al. 2009 Toxic effects of dopamine metabolism in Parkinson's disease Parkinsonism Relat Disord 15 Suppl 1 S35 S38 19131041 10.1016/S1353-8020(09)70010-0
24. A Agil, et al. 2006 Plasma lipid peroxidation in sporadic Parkinson's disease. Role of the L-dopa J Neurol Sci 240 31 36 16219327 10.1016/j.jns.2005. 08.016 1:CAS:528:DC%2BD2MXhtlCrt7rI (Pubitemid 41814950)
25. H Bernheimer, et al. 1973 Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations J Neurol Sci 20 415 455 4272516 10.1016/0022-510X(73)90175-5 1:CAS:528:DyaE28XlvFSgt7k%3D
26. A Kanthasamy, et al. 2010 Novel cell death signaling pathways in neurotoxicity models of dopaminergic degeneration: relevance to oxidative stress and neuroinflammation in Parkinson's disease Neurotoxicology 31 555 561 20005250 10.1016/j.neuro.2009.12.003 1:CAS:528:DC%2BC3cXhtFWqs7fK
27. KR Hoyt IJ Reynolds TG Hastings 1997 Mechanisms of dopamine-induced cell death in cultured rat forebrain neurons: interactions with and differences from glutamate-induced cell death Exp Neurol 143 269 281 9056389 10.1006/exnr.1996. 6374 1:CAS:528:DyaK2sXit1art7s%3D (Pubitemid 27148231)
28. SB Berman TG Hastings 1997 Inhibition of glutamate transport in synaptosomes by dopamine oxidation and reactive oxygen species J Neurochem 69 1185 1195 9282942 10.1046/j.1471-4159.1997.69031185.x 1:CAS:528: DyaK2sXls1Chtbo%3D (Pubitemid 27364840)
29. DM Kuhn RE Arthur Jr 1999 L-DOPA-quinone inactivates tryptophan hydroxylase and converts the enzyme to a redox-cycling quinoprotein Brain Res Mol Brain Res 73 78 84 10581400 10.1016/S0169-328X(99)00238-7 1:CAS:528:DyaK1MXns1ahtL8%3D
30. DM Kuhn, et al. 1999 Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease J Neurochem 73 1309 1317 10461926 10.1046/j.1471-4159.1999.0731309.x 1:CAS:528:DyaK1MXlsVOiurw%3D (Pubitemid 29395493)
31. FH Khan, et al. 2005 Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson's disease Biochim Biophys Acta 1741 65 74 15925494 (Pubitemid 40824991)
32. VS Van Laar, et al. 2009 Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells Neurobiol Dis 34 487 500 19332121 10.1016/j.nbd.2009.03.004
33. FH Khan M Saha S Chakrabarti 2001 Dopamine induced protein damage in mitochondrial-synaptosomal fraction of rat brain Brain Res 895 245 249 11259784 10.1016/S0006-8993(00)03284-4 1:CAS:528:DC%2BD3MXitVOnsLo%3D (Pubitemid 32231162)
34. S Jana, et al. 2011 Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: Implications in dopamine cytotoxicity and pathogenesis of Parkinson's disease Biochim Biophys Acta 1812 663 673 21377526 1:CAS:528:DC%2BC3MXkvVGksLw%3D
35. KA Conway, et al. 2001 Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct Science 294 1346 1349 11701929 10.1126/science.1063522 1:CAS:528:DC%2BD3MXotlKmurk%3D (Pubitemid 33063102)
36. I Miyazaki M Asanuma 2009 Approaches to prevent dopamine quinone-induced neurotoxicity Neurochem Res 34 698 706 18770028 10.1007/s11064-008-9843-1 1:CAS:528:DC%2BD1MXivVajsLs%3D
37. I Miyazaki, et al. 2007 Protective effects of metallothionein against dopamine quinone-induced dopaminergic neurotoxicity FEBS Lett 581 5003 5008 17910954 10.1016/j.febslet.2007.09.046 1:CAS:528:DC%2BD2sXhtFGku7bM (Pubitemid 47531776)
38. M Asanuma, et al. 2008 Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation Neurosci Res 60 106 113 18022268 10.1016/j.neures.2007.10.002 1:CAS:528:DC%2BD1cXisFyksQ%3D%3D